Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis

Objective: to compare the clinical efficacy in real clinical practice of the targeted synthetic disease-modifying antirheumatic drug (sDMARD) tofacitinib (TOFA) and the biologic DMARD (bDMARD), an inhibitor of tumor necrosis factor alpha (TNFα), adalimumab (ADA) in patients with psoriatic arthritis...

Celý popis

Podrobná bibliografie

Hlavní autoři:	E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, S. I. Glukhova, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patrikeyeva, E. L. Nasonov
Médium:	Artigo
Jazyk:	Russo
Vydáno:	IMA-PRESS LLC 2021-06-01
Edice:	Современная ревматология
Témata:	psoriatic arthritis tofacitinib adalimumab biologic disease-modifying antirheumatic drug targeted synthetic disease-modifying antirheumatic drug remission minimal disease activity
On-line přístup:	https://mrj.ima-press.net/mrj/article/view/1145
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!